Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 5/20 | 0.44 |
| ▸ | NOTCH3 | Q9UM47 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | BRD2 | P25440 | 6/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548754 | 1.00 | NOTCH1 (0.44) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL7550811 | 0.88 | BRD4 (0.45) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL7550804 | 0.88 | BRD4 (0.45) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL7551528 | 0.87 | NOTCH1 (0.43) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL7551538 | 0.87 | NOTCH1 (0.43) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL9256006 | 0.86 | CCKBR (0.51) | CCKBR | |
| SCHEMBL6302368 | 0.86 | CCKBR (0.51) | CCKBR | |
| SCHEMBL7544237 | 0.86 | CCKBR (0.51) | CCKBR | |
| SCHEMBL7545546 | 0.85 | BRD4 (0.43) | NOTCH1NOTCH3BRD4BRD2BRD3 | |
| SCHEMBL7544346 | 0.85 | BRD4 (0.43) | NOTCH1NOTCH3BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | NOTCH1 3631/4885NOTCH3 4224/4885BRD4 179/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | NOTCH1 3631/4885NOTCH3 4224/4885BRD4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.